UNCY vs UPB

Unicycive Therapeutics, Inc. vs Upstream Bio, Inc. — Valuation Comparison 2026

UNCY

Biotechnology
Unicycive Therapeutics, Inc.
Quality
4.3
out of 10
Value Trap
36
LOW
Price
$7.02
Last close
Models
9/13
Active
VS

UPB

Biotechnology
Upstream Bio, Inc.
Quality
5.9
out of 10
Value Trap
12
SAFE
Price
$8.32
Last close
Models
9/13
Active

Model-by-Model Comparison

ModelType UNCY Fair ValueUNCY Upside UPB Fair ValueUPB Upside
Bayesian DCF Intrinsic $2.65 -62.3% $3.18 -61.8%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
Markov DDM Intrinsic $0.56 -92.7%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.54 -78.0% $5.79 -30.4%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for UNCY vs UPB — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

UNCY vs UPB — Which Stock Is More Undervalued?

UPB scores higher with a 5.9/10 quality rating vs UNCY's 4.3/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Unicycive Therapeutics, Inc. (UNCY) and Upstream Bio, Inc. (UPB) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

UNCY currently trades at $7.02 with a QOC of 4.3/10, while UPB trades at $8.32 with a QOC of 5.9/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).